INSIGHTS

 
 
FDA Approves Moderna Vaccine
COVID Reports William Haworth COVID Reports William Haworth

FDA Approves Moderna Vaccine

Approval of Moderna's vaccine late Friday under an Emergency Use Authorization by the FDA ensures millions more doses are now en route to distribution centers across the nation. Planes and trucks filled with Moderna's COVID immunization began journeys to distribution centers in every state Sunday morning. Healthcare supply chain giant McKesson is handling the distribution for Moderna from its centers in Kentucky and Mississippi. Pfizer mostly is utilizing the U.S. Government, predominately through the military, for dissemination. McKesson will utilize FedEx and UPS for delivery of its vaccine. Many of the Moderna shipments are being accompanied by local and state police.

Read More
Vaccine Messaging: What does leadership look like?
Policy Briefs Thomas Bowman Policy Briefs Thomas Bowman

Vaccine Messaging: What does leadership look like?

Is it better for the head of a company to get vaccinated last after their employees, or first in a demonstration of behavior-modeled leadership? Many businesses and organizations around the country are grappling with this very chicken-or-egg situation now that a vaccine is within sight. Nationwide, nearly 40 percent of Americans remain hesitant to take the coronavirus vaccine, and while many leaders and celebrity influencers will be part of a $50M PR campaign, some large organizations like businesses and school systems should consider internal messaging and advocacy to reduce the percent of vaccine hesitant individuals...

Read More
Now is the Winter of Our Discontent
COVID Reports William Haworth COVID Reports William Haworth

Now is the Winter of Our Discontent

Dr. Anthony Fauci has repeatedly said that “the cavalry is coming” when he speaks of the advent of forthcoming vaccines — particularly the two leading contenders, Pfizer/BioNTech and Moderna. But these revolutionary developments utilizing first-ever technology never before applied against a pandemic, or perennial infectious diseases like influenza or measles, won’t be available to quell the overwhelming surge in COVID-19 cases nationwide. Every public health expert is warning the most horrific period of the pandemic has yet to unfold…

Read More
A Guide to Combat COVID-19 Conspiracy Theories
COVID Reports RSG COVID Reports RSG

A Guide to Combat COVID-19 Conspiracy Theories

Many of the vaccine conspiracy theories are fueled by a lack of information about vaccine ingredients. This can be countered through a public awareness campaign explaining how the vaccines are made. The following is a survey of common conspiracies related to COVID-19 and the upcoming vaccines and a science-based refutation of the misinformation…

Read More
COVID Vaccine Distribution: A four-phase plan
COVID Reports William Haworth COVID Reports William Haworth

COVID Vaccine Distribution: A four-phase plan

Pfizer, in cooperation with German-based BioNTech, crossed an historic milestone this week when they submitted to the Food and Drug Administration an emergency use authorization (EUA) for a COVID-19 vaccine. The data will quickly be analyzed by FDA and then submitted to an independent advisory panel in early December for approval, which then also will receive a necessary ‘green light’ from the Centers for Disease Control, particularly regarding the rollout process for Pfizer/BioNTech’s vaccine on a prioritization scale. Read more…

Read More
5 Steps to Survive Until A COVID Vaccine is Available
COVID Reports Thomas Bowman COVID Reports Thomas Bowman

5 Steps to Survive Until A COVID Vaccine is Available

Public health experts don’t expect a coronavirus vaccine to become widely available until around April 2021. Even once a viable vaccine candidate is approved, the government must manage an unprecedented fill-and-finish campaign and launch PSAs to combat misinformation that could depress vaccination rates. Until such time, society will have to survive through abiding by published health guidance, which we reiterate here:

Read More
Oxford Vaccine Progress
COVID Reports William Haworth COVID Reports William Haworth

Oxford Vaccine Progress

AstraZeneca is now reporting its AZD1222 COVID-19 mRNA vaccine could be available as early as January of next year. Long favored in the epidemiological community as one of the more likely effective and safe vaccines in development by several major pharmaceutical companies, AstraZeneca’s teaming with Oxford University is now in late-stage trials in Britain and the U.S., as well as other countries, to determine the vaccine’s efficacy and safety.

Read More
Vaccines Progress, FDA Approves Useless Treatment
COVID Reports RSG COVID Reports RSG

Vaccines Progress, FDA Approves Useless Treatment

There is good news out of Oxford, which said that the vaccine it developed with Astra Zeneca worked well and triggered a robust immune response in volunteers. Despite the good news, the UK government is warning that a widespread rollout of a coronavirus vaccine is unlikely before Christmas. The government added that the possibility of wider spread use of vaccines isn't going to happen until the spring of next year at the earliest. We would have enough doses and enough understanding of the medical infrastructure to distribute them effectively by that time.

Read More
Coronavirus Strategy Guide: Schools as a disease vector</em>
COVID Reports RSG COVID Reports RSG

Coronavirus Strategy Guide: Schools as a disease vector

The long-delayed CDC guidance on school re-openings is unscientific, dangerous, and wrong. It indicates that President Trump succeeded in politicizing the recommendations of the CDC. This move is in-line with others that undermine the validity of U.S. data, including long-delays in test results. The U.S. is covering up official numbers and guidance, placing it on a clear trajectory for a worst-case scenario, in-line with other authoritarian countries like Brazil.

Read More